Glenmark successfully developed the active pharmaceutical ingredient (API) and the formulation for
FabiFlu® through its own in-house R&D team. Glenmark filed the product for clinical trial with India’s
drug regulator DCGI and became the first pharmaceutical company in India to receive approval for
conducting phase 3 clinical trial on mild to moderate COVID-19 patients
0 Comments